Evidence map›Paper›PMID 41380159›Full record

ArticleObstetrics and gynecology2026

Effectiveness of 2023-2024 Coronavirus Disease 2019 (COVID-19) Vaccines in Pregnant Women.

Allison Avrich Ciesla, Victoria Lazariu, Janet A Watts, Gabriela Vazquez-Benitez, Kristin Dascomb, Stephanie A Irving, Nicola P Klein, Shaun J Grannis, Toan C Ong, Sarah W Ball and 23 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Obstetrics and gynecology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors.

Allison Avrich CieslaCoronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia; Eagle Health Analytics, San Antonio, Texas; Westat and the Commissioned Corps of the U.S. Public Health Service, Rockville, Maryland; HealthPartners Institute, Minneapolis, Minnesota; the Division of Infectious Diseases and Clinical Epidemiology, Intermountain Health, Salt Lake City, Utah; the Kaiser Permanente Center for Health Research, Portland, Oregon; the Kaiser Permanente Northern California Division of Research, Kaiser Permanente Vaccine Study Center, Oakland, California; the Indiana University School of Medicine, the Regenstrief Institute Center for Biomedical Informatics, the Richard M. Fairbanks School of Public Health, and the Department of Pediatrics, School of Medicine, Indiana University, Indianapolis, Indiana; the University of Colorado School of Medicine, Aurora, Colorado; and the Department of Biomedical Informatics, Columbia University Irving Medical Center, and NewYork-Presbyterian Hospital, New York, New York.
Victoria Lazariu
Janet A Watts
Gabriela Vazquez-Benitez
Kristin Dascomb
Stephanie A Irving
Nicola P Klein
Shaun J Grannis
Toan C Ong
Sarah W Ball
Malini DeSilva
Tamara Sheffield
Daniel Bride
Joshua Van Otterloo
Julie Arndorfer
Allison L Naleway
Padma Koppolu
Bruce Fireman
John Hansen
Julius Timbol
Brian E Dixon
Colin Rogerson
William Fadel
Michelle A Barron
David Mayer
Catia Chavez
Yan Zhuang
Angela Cheung
Lawrence Reichle
Karthik Natarajan
Amanda B Payne
Ruth Link-Gelles
Ousseny Zerbo

Funding

COVID-19 Vaccine Effectiveness in Pregnant Women and their InfantsR01AI168373 · NIAID · KAISER FOUNDATION RESEARCH INSTITUTE · PI Ousseny Zerbo · 2022 to 2026
$2.7M
CDC HHS 75D30121D12779CDC HHS 75D30123C17595Intramural CDC HHS CC999999NIAID NIH HHS R01 AI168373
6 · The paper itself

Abstract

Pregnant women are at higher risk of severe coronavirus disease 2019 (COVID-19) compared with nonpregnant women of reproductive age. During 2023-2024, the Centers for Disease Control and Prevention recommended COVID-19 vaccination for everyone aged 6 months or older, including pregnant women. Using a test-negative design, we assessed the effectiveness of 2023-2024 COVID-19 vaccines against COVID-19-associated emergency department (ED) and urgent care setting encounters among pregnant women aged 18-45 years presenting for care with COVID-19 symptoms from September 2023 to August 2024. Vaccine effectiveness against COVID-19-associated ED and urgent care encounters of one 2023-2024 COVID-19 vaccine dose was 58% (95% CI, 24-77%) among pregnant women and 37% (95% CI, 29-44%) among nonpregnant women of the same age. The 2023-2024 COVID-19 vaccines were associated with a decrease in COVID-19-associated ED and urgent care encounters among pregnant women and nonpregnant women of reproductive age.

Indexed as

COVID-19COVID-19 VaccinesPregnancy Complications, InfectiousVaccine EfficacyAdolescentAdultEmergency Service, HospitalFemaleHumansMiddle AgedPregnancyPregnant PeopleSARS-CoV-2United StatesYoung AdultCOVID-19 Vaccines

Identifiers

PMID41380159
PMCPMC13618793

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.